Next-Generation Antibody-Drug Conjugates Make Their Mark in Breast Cancer
Efforts to Target NRG1 Unlock New Pathways for Treatment
Early data have demonstrated poor outcomes for patients with NRG1 fusions, and limited efficacy with available treatments represents a need for the development of novel therapeutic agents.
Investigators Tackle the Untapped Potential of Personalized Medicine
Improving patient outcomes is top of mind for investigators at John Theurer Cancer Center in Hackensack, New Jersey.
Unprecedented Advances Fuel Progress in the Treatment of AL Amyloidosis
Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.
Relapsed/Refractory Follicular Lymphoma Has a Bounty of Options in the Third Line
Caron A. Jacobson, MD, MMSc, and a panel of experts, talk about the evolving landscape for patients with relapsed or refractory follicular lymphoma, plus data on PI3K inhibitors and CAR T-cell therapies.
Key Data Illuminate New Directions in HER2-Positive Metastatic Breast Cancer Landscape
An abundance of riches in the form of new data for HER2-targeted agents continues to drive progress for patients with metastatic breast cancer.
Taming the Wild West: the View From the FDA
Julia A. Beaver, MD discusses the need for greater collaboration among industry sponsors on diagnostics, regulatory submissions, and multinational clinical trials involving PD-1/PD-L1 immune checkpoint inhibitors.
A Focus on Patient-First Care Drives Breast Cancer Investigator to Success
Joyce A. O’Shaughnessy, MD, the 2016 Giant of Cancer Care® for Community Outreach/Education, explains her continued commitment to impacting change in the space and aiding other oncologists.
First-in-Class AR Agonist Opens Doors for ER-Positive Metastatic Breast Cancer
Androgen recepter positivity serves as an independent predictor of beneficial outcomes in breast cancer.
Checkpoint Inhibitor Changes Take Hold: Approval Standards Stir Debate
the development of PD-1/PD-L1 immune checkpoint inhibitor therapy underwent a course correction in 2021, with the withdrawal of a range of indications due to study results that failed to reach thresholds for confirming clinical benefit.
Objectively Accurate Interpretation of Clinical Trials Results Poses a Challenge
Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.